Olaparib in Metastatic Castration-Resistant Prostate Cancer. Reply

Affiliations

¹ Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
² AstraZeneca, Cambridge, United Kingdom.
³ Institute of Cancer Research, London, United Kingdom.

Comment

Maha Hussain et al. N Engl J Med. 2021.

. 2021 Mar 25;384(12):1175-1176.

doi: 10.1056/NEJMc2100225.

¹ Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
² AstraZeneca, Cambridge, United Kingdom.
³ Institute of Cancer Research, London, United Kingdom.

No abstract available

Comment on

Olaparib in Metastatic Castration-Resistant Prostate Cancer.
McCaw ZR, Liu MA, Wei LJ. McCaw ZR, et al. N Engl J Med. 2021 Mar 25;384(12):1174. doi: 10.1056/NEJMc2100225. N Engl J Med. 2021. PMID: 33761221 No abstract available.
Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Biswas B, Ganguly S, Ghosh J. Biswas B, et al. N Engl J Med. 2021 Mar 25;384(12):1174-1175. doi: 10.1056/NEJMc2100225. N Engl J Med. 2021. PMID: 33761222 No abstract available.
Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Smith TJ. Smith TJ. N Engl J Med. 2021 Mar 25;384(12):1175. doi: 10.1056/NEJMc2100225. N Engl J Med. 2021. PMID: 33761223 No abstract available.